Mariner Wealth Advisors (NYC)’s Vertex Pharmaceuticals VRTX Stock Holding History

Mariner Wealth Advisors (NYC)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$15K	Buy	+125	New	+$15K	0.01%	314

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Mariner Wealth Advisors (NYC)'s VRTX Position: Q1 2015 in Review

Mariner Wealth Advisors (NYC) opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2015: 125 shares worth $15K. The stake represents 0.01% of the portfolio and ranks #314 among its holdings.

480 funds tracked by Wall St. Rank hold VRTX as of Q1 2015.

Mariner Wealth Advisors (NYC) held 125 shares of Vertex Pharmaceuticals worth $15K as of Q1 2015.
Vertex Pharmaceuticals was a new Mariner Wealth Advisors (NYC) position in Q1 2015.
Vertex Pharmaceuticals made up 0.01% of Mariner Wealth Advisors (NYC)'s portfolio in Q1 2015, its #314 holding.
480 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2015.

Based on Mariner Wealth Advisors (NYC)'s 13F filing for Q1 2015, filed 14 May 2015.